0001333277-19-000034.txt : 20190208
0001333277-19-000034.hdr.sgml : 20190208
20190208202109
ACCESSION NUMBER: 0001333277-19-000034
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190207
FILED AS OF DATE: 20190208
DATE AS OF CHANGE: 20190208
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GOLDFISCHER CARL
CENTRAL INDEX KEY: 0001110780
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36500
FILM NUMBER: 19581563
MAIL ADDRESS:
STREET 1: 161 WEST 61ST STREET
CITY: NEW YORK
STATE: NY
ZIP: 10022
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CymaBay Therapeutics, Inc.
CENTRAL INDEX KEY: 0001042074
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943103561
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7575 GATEWAY BOULEVARD
STREET 2: SUITE 110
CITY: NEWARK
STATE: CA
ZIP: 94560
BUSINESS PHONE: 510-293-8800
MAIL ADDRESS:
STREET 1: 7575 GATEWAY BOULEVARD
STREET 2: SUITE 110
CITY: NEWARK
STATE: CA
ZIP: 94560
FORMER COMPANY:
FORMER CONFORMED NAME: METABOLEX, INC.
DATE OF NAME CHANGE: 20090721
FORMER COMPANY:
FORMER CONFORMED NAME: METABOLEX INC
DATE OF NAME CHANGE: 19970710
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2019-02-07
0001042074
CymaBay Therapeutics, Inc.
CBAY
0001110780
GOLDFISCHER CARL
C/O CYMABAY THERAPEUTICS, INC.
7575 GATEWAY BOULEVARD, SUITE 110
NEWARK
CA
94560
1
0
0
0
Common Stock
2019-02-07
4
M
0
2335
5.00
A
2335
D
Common Stock
2019-02-07
4
M
0
9340
5.50
A
11675
D
Common Stock
2019-02-07
4
S
0
11675
9.0217
D
0
D
Stock Option (right to buy)
5.00
2019-02-07
4
M
0
2335
0
D
2023-12-22
Common Stock
2335
0
D
Stock Option (right to buy)
5.50
2019-02-07
4
M
0
9340
0
D
2027-06-27
Common Stock
9340
0
D
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.00 to $9.09, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Fully vested.
/s/ Sujal Shah, as attorney-in-fact
2019-02-08